News

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab (Keytruda®) compared to PD-L1 at the upcoming National Comprehensive Cancer Network (NCCN) Annual Conference. The study, conducted with I-SPY 2 clinical trial results, evaluated five different PD-L1 antibodies – including the one most commonly used as a companion diagnostic – yet only MHC-II expression showed a statistically significant correlation with patient outcomes.

02/24/2025

Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

Golden, CO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA) code 0249U – originally issued to Theralink Technologies, Inc. – to Ignite Proteomics LLC. The AMA CPT code is listed on the Medicare Clinical Laboratory Fee Schedule (CLFS) and is addressed by the Palmetto GBA MolDx “Proteomics Testing” article (A59636). This milestone integrates both the laboratory capability and the owned and licensed intellectual property of the proteomic breast cancer assay into Ignite Proteomics.

02/19/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is IMAC Holdings, Inc. (BACK) a buy, sell, or hold?

IMAC Holdings, Inc. (BACK) can sell. Click on Rating Page for detail.

What is IMAC Holdings, Inc.'s stock price?

The price of IMAC Holdings, Inc. (BACK) is 0.0316 and it was updated on 2025-05-13 07:01:13.

Is IMAC Holdings, Inc. (BACK) overvalued or undervalued?

Currently IMAC Holdings, Inc. (BACK) is in undervalued.

News

From:

To:

News
Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), announces the publication of a significant study in the British Journal of Cancer titled "Functional activation of the AKT–mTOR signalling axis in a real-world metastatic breast cancer cohort". Mon, Feb. 10, 2025
IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”) has launched Ignite Proteomics LLC (“Ignite”), its new subsidiary dedicated to helping doctors select the most effective cancer treatments based on protein-level insights. This move addresses a growing need for better, faster ways to personalize therapy in breast cancer and beyond. Mon, Jan. 27, 2025
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q FRANKLIN, TN, Nov. 22, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC” or the “Company”) (NASDAQ: BACK) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on November 22, 2024 (the “Notice”). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Form 10-Q”), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the “Form 12b-25”) filed with the Securities and Exchange Commission (the “SEC”) on November 15, 2024. The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC. Fri, Nov. 22, 2024
IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1) FRANKLIN, TN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC” or the “Company”) (NASDAQ: BACK) today announced that it has received an exception from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). This exception extends the deadline for the Company to file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Form 10-Q”) until February 17, 2025. Thu, Nov. 14, 2024
IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”), a leader in innovative healthcare solutions, proudly announces the launch of an entirely new precision oncology assay for breast cancer treatment decision making utilizing the Reverse Phase Protein Array (RPPA) technology through its newly established subsidiary, Ignite Proteomics LLC (“Ignite Proteomics”). This launch follows IMAC Holdings' strategic acquisition of key assets from Theralink Technologies, Inc., and is underscored by a landmark clinical case study “ Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer”, demonstrating the power of RPPA technology in precision oncology published in npj Precision Oncology, an international, peer-reviewed journal focused on precision oncology. Thu, Sep. 19, 2024

SEC Filings

SEC Filings
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 04/28/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 04/18/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 04/16/2025
IMAC Holdings, Inc. (BACK) - 10-K - Current report SEC Filings 04/15/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 04/09/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 04/03/2025
IMAC Holdings, Inc. (BACK) - NT 10-K - Current report SEC Filings 03/31/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 03/31/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 03/27/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 03/25/2025
IMAC Holdings, Inc. (BACK) - SCHEDULE 13G/A SEC Filings 03/18/2025
IMAC Holdings, Inc. (BACK) - 5 SEC Filings 03/18/2025
IMAC Holdings, Inc. (BACK) - 4 SEC Filings 03/18/2025
IMAC Holdings, Inc. (BACK) - DEFA14A SEC Filings 03/14/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 03/14/2025
IMAC Holdings, Inc. (BACK) - 4 SEC Filings 03/14/2025
IMAC Holdings, Inc. (BACK) - 3 SEC Filings 03/14/2025
IMAC Holdings, Inc. (BACK) - SCHEDULE 13G SEC Filings 03/13/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 03/07/2025
IMAC Holdings, Inc. (BACK) - DEFA14A SEC Filings 03/04/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 03/04/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 02/28/2025
IMAC Holdings, Inc. (BACK) - 424B5 SEC Filings 02/19/2025
IMAC Holdings, Inc. (BACK) - EFFECT SEC Filings 02/18/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 02/18/2025
IMAC Holdings, Inc. (BACK) - 424B5 SEC Filings 02/14/2025
IMAC Holdings, Inc. (BACK) - S-1/A SEC Filings 02/13/2025
IMAC Holdings, Inc. (BACK) - S-1/A SEC Filings 02/12/2025
IMAC Holdings, Inc. (BACK) - DEFA14A SEC Filings 02/11/2025
IMAC Holdings, Inc. (BACK) - DEF 14A SEC Filings 02/11/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 02/11/2025
IMAC Holdings, Inc. (BACK) - PRE 14A SEC Filings 01/27/2025
IMAC Holdings, Inc. (BACK) - S-1/A SEC Filings 01/24/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 01/23/2025
IMAC Holdings, Inc. (BACK) - 10-Q - Quarterly Report SEC Filings 01/17/2025
IMAC Holdings, Inc. (BACK) - 4 SEC Filings 01/02/2025
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 12/20/2024
IMAC Holdings, Inc. (BACK) - 10-Q - Quarterly Report SEC Filings 12/18/2024
IMAC Holdings, Inc. (BACK) - 8-K/A - Current report SEC Filings 11/22/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 11/22/2024
IMAC Holdings, Inc. (BACK) - NT 10-Q - Quarterly Report SEC Filings 11/15/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 11/14/2024
IMAC Holdings, Inc. (BACK) - 8-K/A - Current report SEC Filings 11/13/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 11/13/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 10/23/2024
IMAC Holdings, Inc. (BACK) - 3 SEC Filings 10/07/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 09/27/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 09/25/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 09/13/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 09/12/2024
IMAC Holdings, Inc. (BACK) - 4 SEC Filings 09/11/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 08/30/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 08/23/2024
IMAC Holdings, Inc. (BACK) - NT 10-Q - Quarterly Report SEC Filings 08/15/2024
IMAC Holdings, Inc. (BACK) - DEF 14A SEC Filings 07/30/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 07/30/2024
IMAC Holdings, Inc. (BACK) - 8-K/A - Current report SEC Filings 07/18/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 07/18/2024
IMAC Holdings, Inc. (BACK) - 3 SEC Filings 07/09/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 07/08/2024
IMAC Holdings, Inc. (BACK) - 3 SEC Filings 07/08/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 07/02/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 06/18/2024
IMAC Holdings, Inc. (BACK) - S-1 SEC Filings 06/13/2024
IMAC Holdings, Inc. (BACK) - PRE 14A SEC Filings 06/06/2024
IMAC Holdings, Inc. (BACK) - 3 SEC Filings 05/31/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 05/24/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 05/16/2024
IMAC Holdings, Inc. (BACK) - 10-Q - Quarterly Report SEC Filings 05/15/2024
IMAC Holdings, Inc. (BACK) - RW SEC Filings 05/07/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 05/07/2024
IMAC Holdings, Inc. (BACK) - 10-K/A - Current report SEC Filings 05/02/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 05/01/2024
IMAC Holdings, Inc. (BACK) - D SEC Filings 04/25/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 04/16/2024
IMAC Holdings, Inc. (BACK) - 10-K - Current report SEC Filings 04/16/2024
IMAC Holdings, Inc. (BACK) - NT 10-K - Current report SEC Filings 04/01/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 02/23/2024
IMAC Holdings, Inc. (BACK) - 25-NSE SEC Filings 02/09/2024
IMAC Holdings, Inc. (BACK) - S-4/A SEC Filings 01/11/2024
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 12/29/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 12/27/2023
IMAC Holdings, Inc. (BACK) - 4 SEC Filings 12/27/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 11/30/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 11/24/2023
IMAC Holdings, Inc. (BACK) - 10-Q - Quarterly Report SEC Filings 11/21/2023
IMAC Holdings, Inc. (BACK) - NT 10-Q - Quarterly Report SEC Filings 11/14/2023
IMAC Holdings, Inc. (BACK) - S-4/A SEC Filings 11/13/2023
IMAC Holdings, Inc. (BACK) - S-4/A SEC Filings 11/09/2023
IMAC Holdings, Inc. (BACK) - S-4 SEC Filings 09/29/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 09/27/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 09/08/2023
IMAC Holdings, Inc. (BACK) - 10-Q - Quarterly Report SEC Filings 08/21/2023
IMAC Holdings, Inc. (BACK) - NT 10-Q - Quarterly Report SEC Filings 08/14/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 08/04/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 07/28/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 07/06/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 06/02/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 05/26/2023
IMAC Holdings, Inc. (BACK) - 425 SEC Filings 05/26/2023
IMAC Holdings, Inc. (BACK) - 10-Q - Quarterly Report SEC Filings 05/19/2023
IMAC Holdings, Inc. (BACK) - NT 10-Q - Quarterly Report SEC Filings 05/15/2023
IMAC Holdings, Inc. (BACK) - DEF 14A SEC Filings 05/11/2023
IMAC Holdings, Inc. (BACK) - PRE 14A SEC Filings 04/24/2023
IMAC Holdings, Inc. (BACK) - 10-K - Current report SEC Filings 03/31/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 03/24/2023
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 03/03/2023
IMAC Holdings, Inc. (BACK) - SC 13G/A SEC Filings 02/07/2023
IMAC Holdings, Inc. (BACK) - SC 13G SEC Filings 01/23/2023
IMAC Holdings, Inc. (BACK) - 10-Q - Quarterly Report SEC Filings 11/14/2022
IMAC Holdings, Inc. (BACK) - 4 SEC Filings 10/20/2022
IMAC Holdings, Inc. (BACK) - EFFECT SEC Filings 10/14/2022
IMAC Holdings, Inc. (BACK) - CORRESP SEC Filings 10/11/2022
IMAC Holdings, Inc. (BACK) - S-3/A SEC Filings 10/07/2022
IMAC Holdings, Inc. (BACK) - CORRESP SEC Filings 10/07/2022
IMAC Holdings, Inc. (BACK) - UPLOAD SEC Filings 09/30/2022
IMAC Holdings, Inc. (BACK) - S-3 SEC Filings 09/26/2022
IMAC Holdings, Inc. (BACK) - 8-K - Current report SEC Filings 09/26/2022

Press Releases

StockPrice Release
Ignite proteomics to present data on mhc-ii as a predictor of pembrolizumab response at nccn annual conference 02/24/2025
Ignite proteomics completes acquisition of pla code 0249u for its advanced proteomic breast cancer assay 02/19/2025
Ignite proteomics announces publication of study demonstrating superiority of protein activation analysis in predicting breast cancer therapy response 02/10/2025
Imac holdings introduces ignite proteomics: a new standard for matching patients with the right cancer therapies 01/27/2025
Imac holdings receives notification of deficiency from nasdaq related to delayed filing of quarterly report on form 10-q 11/22/2024
Imac holdings granted extension by nasdaq to regain compliance with listing rule 5250(c)(1) 11/14/2024
Imac holdings inc. launches subsidiary ignite proteomics and announces groundbreaking precision oncology case study utilizing rppa technology 09/19/2024
Imac holdings receives notification of deficiency from nasdaq related to delayed filing of quarterly report on form 10-q 08/23/2024
Imac holdings, inc. appoints dr. matthew schwartz and dr. peter beitsch to board of directors 07/11/2024
Imac holdings announces leadership succession 05/24/2024
Imac holdings acquires assets of theralink to continue precision medicine business 05/07/2024
Imac holdings, inc. regains compliance with nasdaq listing requirements 09/27/2023
Imac holdings, inc. announces 1-for-30 reverse stock split 09/07/2023
Imac holdings announces $4.3 million private placement of convertible preferred stock and warrants priced at the market 07/26/2023
Imac holdings annual meeting of shareholders reminder 06/28/2023
Theralink investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates merger of theralink technologies, inc. - ther 05/30/2023
Back stock alert: halper sadeh llc is investigating whether the merger of imac holdings, inc. is fair to shareholders 05/23/2023
Theralink® signs definitive merger agreement to be acquired by imac holdings, a nasdaq listed company 05/23/2023
Theralink® signs definitive merger agreement to be acquired by imac holdings, a nasdaq listed company 05/23/2023
Imac holdings reports year end 2022 financial results and corporate update 03/31/2023
Imac holdings and brain scientific announce a strategic merger to create synergistic end-to-end neurological solution 03/20/2023
Imac holdings, inc announces the sale of the backspace 03/01/2023
Imac holdings, inc. hosts hall of fame athlete panel at the evoke conference to launch whole food supplement partnership 10/21/2022
Imac holdings, inc. announces completion of third cohort of its phase 1 clinical study of umbilical cord-derived mesenchymal stem cells for the treatment of bradykinesia due to parkinson's disease 09/09/2022
Biote announces strategic partnership with imac holdings, inc. 09/07/2022
Imac holdings, inc. announces addition of medical weight loss services to imac regeneration centers 09/01/2022
Imac holdings reports record revenue of $5m in second quarter 08/15/2022

More Headlines

News
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q FRANKLIN, TN, Aug. 23, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC” or the “Company”) (NASDAQ: BACK) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on August 21, 2024 (the “Notice”). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Form 10-Q”), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the “Form 12b-25”) filed with the Securities and Exchange Commission (the “SEC”) on August 15, 2024. The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC. 08/23/2024
IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors Golden, CO, July 11, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ: BACK) (the “Company” or “IMAC”), a leading innovator in proteomics research and technology, announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move underscores the Company's commitment to advancing its position in the field of proteomics and driving innovation in precision medicine. 07/11/2024
IMAC Holdings Announces Leadership Succession Faith Zaslavsky appointed as CEO to succeed Jeff Ervin FRANKLIN, Tenn., May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC”) today announced leadership transitions to the board of directors and executive team. 05/24/2024
IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ: BACK) (“BACK”) and Theralink Technologies, Inc. (“Theralink”), BACK acquired the assets of Theralink, other than certain excluded assets, in settlement of the default by Theralink of certain outstanding debt and BACK's agreement to issue certain shares of preferred stock of BACK to Theralink and/or certain holders of debt of Theralink, as applicable, in the future following the completion of a third party valuation of Theralink's business. 05/07/2024
IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements Franklin, TN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company”) today announced that it has received notice from The Nasdaq Stock Market LLC informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market and that it is in compliance with all applicable listing standards. 09/27/2023
IMAC Holdings, Inc. Announces 1-for-30 Reverse Stock Split Franklin, TN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company”) today announced a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the “Reverse Split”) and that it had filed a Certificate of Amendment to the Company's Certificate of Incorporation in order to effect the Reverse Split. The Reverse Split will be effective after the market closes on September 7, 2023. Beginning with the opening of trading on September 8, 2023, the Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol “BACK,” but will trade on a split-adjusted basis under a new CUSIP number, 44967K302. 09/07/2023
If You Can Only Buy One Penny Stock, It Better Be One of These 3 Names Penny stocks are generally defined as securities that trade for less than $5 a share. These stocks can be volatile and unpredictable, leading many investors to avoid them. 07/27/2023
IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market Franklin, Tennessee, July 26, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company” ), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments, announced today that it entered into a definitive securities purchase agreement with several institutional and accredited investors, including existing significant investors of Theralink Technologies, Inc., its previously announced merger partner (OTC:THER) (“Theralink”), and Theralink's Chairman, for the sale of its preferred stock and warrants. IMAC sold an aggregate of 2,500 shares of its Series A-1 Convertible Preferred Stock, stated value $1,000 per share, 1,800 shares of its Series A-2 Convertible Preferred Stock, stated value $1,000 per share, and Warrants to purchase up to 62,271,063 shares of its common stock for aggregate gross proceeds of $4,300,000 before deducting placement agent fees and other offering expenses. The shares of A-1 Convertible Preferred Stock, shall bear a 12% dividend, and are initially convertible into an aggregate of 22,893,773 shares of common stock of the Company, and the shares of Series A-2 Convertible Preferred Stock are initially convertible into an aggregate of 16,483,517 shares of common stock of the Company, in each case, at a conversion price of $0.1092 per share. The Warrants have an exercise price of $0.1092 per share, are exercisable immediately, and will expire five years from the date of shareholder approval of this private placement. It is expected that approximately $3.0 million of the proceeds of the offering will be used to make a loan to Theralink for investment into sales and marketing efforts and general working capital purposes as the companies continue to take formal steps together in advancing their merger previously announced on May 23, 2023. 07/26/2023
Imac Holdings (IMAC) Receives a New Rating from Ascendiant Imac Holdings (IMAC) received a Buy rating from Ascendiant analyst Edward Woo today. The company's shares closed last Tuesday at $1.73. According to 04/15/2020
Imac Holdings (IMAC) Receives a New Rating from Ascendiant Imac Holdings (IMAC – Research Report) received a Buy rating from Ascendiant analyst Edward Woo today. The company’s shares closed 04/15/2020

Unlock

BACK Ratings Summary

BACK Quant Ranking